Lecanemab reduces neuropsychiatric symptoms and related regional brain amyloid load in early Alzheimer's disease: a preliminary prospective study (EANM 2026) - Sep 29, 2026 - Abstract #EP-0714; "Our results suggest that NPS improvement after 6 months of lecanemab treatment in early AD may be associated with amyloid reduction and structural changes in related cerebral regions. Preliminary findings demonstrate that lecanemab may confer benefits beyond cognition."
Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Mood Disorders • Psychiatry
|